{"id":501301,"date":"2020-08-10T14:10:02","date_gmt":"2020-08-10T14:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=501301"},"modified":"2020-08-10T14:10:02","modified_gmt":"2020-08-10T14:10:02","slug":"acute-lymphocytic-leukemia-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-lymphocytic-leukemia-market-size-share-trends-epidemiology-forecast-till-2030_501301.html","title":{"rendered":"Acute Lymphocytic Leukemia Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acute Lymphocytic Leukemia Market, Size, Share, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Acute Lymphocytic Leukemia Market, Size, Share, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Acute lymphocytic leukemia Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Acute lymphocytic leukemia (ALL), historical and forecasted epidemiology as well as the Acute lymphocytic leukemia (ALL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">Acute Lymphocytic Leukemia&nbsp;(ALL) is a type of cancer that affects the blood and bone marrow. It starts from young white blood cells called lymphocytes in the bone marrow; mainly characterized by an overproduction of immature white blood cells, called lymphoblasts or leukemic blasts.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Lymphocytic Leukemia Epidemiology Segmentation&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Incident Cases of Leukemia<\/li>\n<li>Total Incident Cases of ALL<\/li>\n<li>Total Incident Cases of ALL Segmented by Age and Gender<\/li>\n<li>Total Subtype-specific Cases of ALL<\/li>\n<li>Total Genetic Mutation-specific Cases of ALL<\/li>\n<li>Total Treated Cases of ALL<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Lymphocytic Leukemia Epidemiology<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total incident cases of ALL in the 7MM in 2017 was 10,341&nbsp;<\/li>\n<li>ALL is more frequent in males compare to females.<\/li>\n<li>The total incident cases of ALL in 2017:-<\/li>\n<li>The United States &#8211; 5,816<\/li>\n<li>Germany &#8211; 942<\/li>\n<li>France&nbsp; &#8211; 857<\/li>\n<li>Spain &#8211; 414<\/li>\n<li>Japan &ndash; 872<\/li>\n<li>The Age-Specific Incident Cases was the most in age-group<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Lymphocytic Leukemia Market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-lymphocytic-leukemia-all-market\" target=\"_blank\"><strong>Acute Lymphocytic Leukemia market size in the 7MM in 2017 was USD 1,246 million<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-lymphocytic-leukemia-all-market\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/dd5af9b1808ec90e7a2fc7c98c92d5a0.jpg\" alt=\"\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Lymphocytic Leukemia Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing Focus Towards the Development of Targeted Therapies<\/li>\n<li>Rising Occurrence of ALL<\/li>\n<li>Improvement in the Diagnosis and Awareness<\/li>\n<li>Competitive Landscape<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Lymphocytic Leukemia Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Financial Impact<\/li>\n<li>Generic Erosion<\/li>\n<li>High Rate of Chemo resistance Development<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Lymphocytic Leukemia&nbsp;Emerging Therapies<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Imbruvica (Ibrutinib): Pharmacyclics (an AbbVie Company)<\/li>\n<li>Jakafi (ruxolitinib): Incyte Corporation\/Novartis<\/li>\n<li>Motixafortide (BL-8040): BioLine Rx<\/li>\n<li>TC-110: TCR2 Therapeutics<\/li>\n<li>Lisocabtagene Maraleucel (JCAR017): Bristol-Myers Squibb<\/li>\n<li>TBI-1501: Takara Bio\/Otsuka Pharmaceuticals<\/li>\n<li>UCART19: Servier\/Allogene<\/li>\n<li>&nbsp;Venetoclax: AbbVie and Roche<\/li>\n<li>NiCord (omidubicel): Gamida Cell Ltd.<\/li>\n<li>&nbsp;Eliquis (apixaban): Bristol-Myers Squibb|Pfizer<\/li>\n<li>Isatuximab: Sanofi<\/li>\n<li>&nbsp;JZP-458 (recombinant Erwinia asparaginase): Jazz Pharmaceuticals<\/li>\n<li>&nbsp;Vyxeos (Daunorubicin and Cytarabine for Injection): Jazz Pharmaceuticals<\/li>\n<li>&nbsp;Daratumumab: Janssen Research &amp; Development<\/li>\n<li>&nbsp;ProTmune: Fate Therapeutics<\/li>\n<li>MB-CART19.1: MiltenyiBiotec B.V. &amp; Co. KG<\/li>\n<li>&nbsp;BPX-501 T Cells (rivogenlecleucel; iC9-CAR19 cells): Bellicum Pharmaceuticals<\/li>\n<li>PBCAR0191: Precision BioSciences\/Servier<\/li>\n<li>&nbsp;AUTO1: Autolus Limited<\/li>\n<li>KTE-X19: Gilead Sciences<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-lymphocytic-leukemia-all-market\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-lymphocytic-leukemia-all-market\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><span>1. Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Executive Summary of Acute lymphocytic leukemia (ALL)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Competitive Intelligence Analysis for Acute lymphocytic leukemia (ALL)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. Acute lymphocytic leukemia (ALL): Market Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1. Acute lymphocytic leukemia (ALL) Total Market Share (%) Distribution in 2017<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.2. Acute lymphocytic leukemia (ALL) Total Market Share (%) Distribution in 2030<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5. Acute lymphocytic leukemia (ALL): Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1. Introduction<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.2. Sign and Symptoms&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.3. Pathophysiology&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.4. Risk Factors&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5. Diagnosis&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>6. Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7. Acute lymphocytic leukemia (ALL) Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.1. Epidemiology Key Findings<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.2. Assumptions and Rationale: 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.3. Epidemiology Scenario: 7MM<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.3.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in the 7MM (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.4. United States Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.4.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in the United States (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>7.5. EU-5 Country-wise Epidemiology<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.1. Germany Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.1.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in Germany (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.2. France Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.2.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in France (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.3. Italy Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.3.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in Italy (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.4. Spain Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.4.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in Spain (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.5. United Kingdom Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.5.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>7.5.6. Japan Epidemiology<\/span><\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\"><span>7.5.6.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in Japan (2017-2030)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.1. Acute lymphocytic leukemia (ALL) Treatment and Management<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.2. Acute lymphocytic leukemia (ALL) Treatment Algorithm&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9. Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. Key Endpoints of Acute lymphocytic leukemia (ALL) Treatment<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11. Marketed Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.1. List of Marketed Products in the 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>11.2. Drug Name: Company Name<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>11.2.1. Product Description<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>11.2.2. Regulatory Milestones<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>11.2.3. Other Developmental Activities<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>11.2.4. Pivotal Clinical Trials<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>11.2.5. Summary of Pivotal Clinical Trial<\/span><\/p>\n<p style=\"text-align: justify;\"><span>List to be continued in report<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12. Emerging Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.1. Key Cross<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>12.2. Drug Name: Company Name<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>12.2.1. Product Description<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>12.2.2. Other Developmental Activities<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>12.2.3. Clinical Development<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>12.2.4. Safety and Efficacy<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>12.2.5. Product Profile<\/span><\/p>\n<p style=\"text-align: justify;\"><span>List to be continued in report<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13. Acute lymphocytic leukemia (ALL): Seven Major Market Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1. Key Findings<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.2. Acute lymphocytic leukemia (ALL) Market Size in 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.3. Acute lymphocytic leukemia (ALL) Market Size by Therapies in the 7MM<\/span><\/p>\n<p style=\"text-align: justify;\"><span>14. Attribute analysis<\/span><\/p>\n<p style=\"text-align: justify;\"><span>15. 7MM: Market Outlook<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.1. United States: Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.1.1. Acute lymphocytic leukemia (ALL) Total Market Size in the United States<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.1.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in the United States<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.2. EU-5 countries: Market Size and Outlook<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.3. Germany Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.3.1. Acute lymphocytic leukemia (ALL) Total Market Size in Germany<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.3.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in Germany<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.4. France Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.4.1. Acute lymphocytic leukemia (ALL) Total Market Size in France<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.4.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in France<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.5. Italy Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.5.1. Acute lymphocytic leukemia (ALL) Total Market Size in Italy<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.5.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in Italy<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.6. Spain Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.6.1. Acute lymphocytic leukemia (ALL) Total Market Size in Spain<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.6.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in Spain<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.7. United Kingdom Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.7.1. Acute lymphocytic leukemia (ALL) Total Market Size in the United Kingdom<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.7.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in the United Kingdom<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>15.8. Japan Market Outlook<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.8.1. Japan Market Size<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.8.2. Acute lymphocytic leukemia (ALL) Total Market Size in Japan<\/span><\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\"><span>15.8.3. Acute lymphocytic leukemia (ALL) Market Size by Therapies in Japan<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16. Access and Reimbursement Overview of Acute lymphocytic leukemia (ALL)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. KOL Views<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18. Market Drivers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19. Market Barriers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>20.1. Bibliography<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>20.2. Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21. DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>22. Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>23. About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acute-lymphocytic-leukemia-market-size-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acute-lymphocytic-leukemia-market-size-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Acute lymphocytic leukemia Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Acute lymphocytic leukemia (ALL), historical and forecasted epidemiology as well as the Acute lymphocytic leukemia (ALL) market trends in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acute-lymphocytic-leukemia-market-size-share-trends-epidemiology-forecast-till-2030_501301.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-501301","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=501301"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501301\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=501301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=501301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=501301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}